Microambiente Tumoral e Inmunoterapia

Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments (Apr, 10.1007/s40265-024-02030-7, 2024)

DRUGS. Correction. 84(5):621-621.
[doi:10.1007/s40265-024-02044-1]

Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRAS^G12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

DRUGS. Review. 84(5):527-548.
[doi:10.1007/s40265-024-02030-7]

Siringo M, Baena J, Bote de Cabo H, Torres-Jiménez J, Zurera M, Zugazagoitia J, Paz-Ares L (2023).

Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer.

Cancers. Review. 15(23).
[doi:10.3390/cancers15235505]

García-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, OJ, Cruz-Castellanos, P, Morán, T, Reguart, N, Zugazagoitia, J, Dómine, M (2023).

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. Correction. 25(9):2760-2762.
[doi:10.1007/s12094-023-03290-7]

Ponce, S, Cedrés, S, Ricordel, C, Isambert, N, Viteri, S, Herrera-Juarez, M, Martinez-Marti, A, Navarro, A, Lederlin, M, Serres, X, Zugazagoitia, J, Vetrhus, S, Jaderberg, M, Hansen, TB, Levitsky, V, Paz-Ares, L (2023).

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Journal For Immunotherapy Of Cancer. Article. 11(9).
[doi:10.1136/jitc-2023-007552]

García-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, O, Cruz-Castellanos, P, Morán, T, Reguart, N, Zugazagoitia, J, Dómine, M (2023).

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 25(9):2679-2691.
[doi:10.1007/s12094-023-03216-3]

Isla, D, Sánchez, A, Casal, J, Cobo, M, Majem, M, Reguart, N, Zugazagoitia, J, Bernabé, R (2023).

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

Journal of Clinical Medicine. Article. 12(15).
[doi:10.3390/jcm12155063]

Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A (2023).

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.

CANCER RESEARCH. Article. 83(15):2513-2526.
[doi:10.1158/0008-5472.CAN-22-3023]

Hernandez, S, Conde, E, Alonso, M, Illarramendi, A, de Cabo, HB, Zugazagoitia, J, Paz-Ares, L, Lopez-Rios, F (2023).

A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

Translational lung cancer research. Review. 12(7):1549-1562.
[doi:10.21037/tlcr-22-855]